4&#39; -substituted leucomycins

ABSTRACT

There are described novel 4′substituted 16-membered macrolides and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier. Also described are a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for the preparation of such compounds

TECHNICAL FIELD

[0001] The present invention relates to novel macrolides having antibacterial activity and useful in the treatment and prevention of bacterial infections. More particularly, the invention relates to a novel class of 4′-substituted 16-membered macrolides, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

BACKGROUND OF THE INVENTION

[0002] Macrolide antibiotics play a therapeutically important role, particularly with the emergence of new pathogens. Structural differences are related to the size of the lactone ring and to the number and nature (neutral or basic) of the sugars. Natural macrolides are classified according to the size of the lactone ring (12, 14, 15 or 16 atoms). The macrolide antibiotic family (14-, 15- and 16-membered ring derivatives) shows a wide range of characteristics (antibacterial spectrum, side-effects and bioavailability). Among the commonly used macrolides are erythromycin and josamycin.

[0003] The 1 6-membered ring macrolide antibiotics constitute an important clinically useful series of naturally occurring compounds within the macrolide class of antibiotics, as they show some advantages over 14-membered ring compounds (gastrointestinal tolerance and activity against strains expressing resistance of the inducible type. Sixteen membered macrolides usually contain an amino disaccharide -4-O-(L-mycarosyl)-D-mycaminose and/or D-desosamine. One class has only neutral sugars. The sixteen membered macrolides can be classified into two major groups—the leucomycins and the tylosin series.

[0004] The leucomycins differ from each other in terms of the acyl group at positions O-3 and O-4″ and the C12, 13 epoxy group. Within a given chromophoric group, it is possible to differentiate the various compounds by the substituent at C-3 and C-4″.

Leucomycin R3 R4 A1 H C(O)CH2CHMe2 (Kitasamycin) A5 H C(O)CH2CH2CH3 A7 H C(O)CH2CH3 A9 H C(O)CH3 V(A11) H H (Josamycin) A3 C(O)CH3 C(O)CH2CHMe2 A4 C(O)CH3 C(O)CH2CH2CH3 A6 C(O)CH3 C(O)CH2CH3 A8 C(O)CH3 C(O)CH3 U C(O)CH3 H Miokamycin¹ C(O)CH2CH3 C(O)CH2CH2CH3 Rokitamycin² H C(O)CH2CH2CH3

[0005] The search for macrolides active against MLS-resistant strains (MLS=Macrolides-Lincosamides-Streptogramines) has become a major goal, together with retaining the overall profile of the macrolides in terms of stability, tolerance and pharmacokinetics. Semisynthetic molecules have recently been developed from erythromycin A; new compounds containing a 14-membered lactone ring with chemical modifications to enhance acid stability and prevent anhydro formation include roxithromycin and clarithromycin.

[0006] However, less research has been done to improve the sixteen membered macrolides to overcome resistance and to improve its acid stability.

SUMMARY OF THE INVENTION

[0007] The present invention provides a novel class of 4′-substituted 16-membered macrolides possessing increased antibacterial activity toward Gram positive and Gram negative bacteria as well as macrolide resistant Gram positives. In addition, the present invention provides a class of 16-membered macrolides that are more acid stable.

[0008] In one embodiment, the present invention provides compounds represented by Formula I, or a pharmaceutically acceptable salt, ester or prodrug thereof:

[0009] In Formula I

[0010] A is selected from the group consisting of;

[0011] (1) CHO or a protected aldehyde,

[0012] (2) CH₂X, wherein X is selected from the group consisting of;

[0013] a. hydroxy or protected hydroxy,

[0014] b. halogen,

[0015] c. NR7R8, wherein R7 and R8 are each independently selected from hydrogen, C1-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic or R7R8 taken with the nitrogen atom to which they are connected form a 3- to 7-membered ring which may optionally contain a hetero function selected from the group consisting of —O—, —NH—, —N(C1-C6-alkyl)-, —N(aryl)-, —N(heteroaryl)-, —S—, —S(O)— and —S(O)₂—,

[0016] d. NR7C(O)—R9, where R7 is as previously defined and R9 is selected from the group consisting of;

[0017] i. C1-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic,

[0018] ii. C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic,

[0019] iii. C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic,

[0020] iv. aryl,

[0021] v. substituted aryl,

[0022] vi. heterocyclic, and

[0023] vii. substituted heterocyclic

[0024] e. NR7C(O)—NR8R9, where R7, R8, and R9 are as previously defined,

[0025] f. S(O)_(n)-R10, where R10 is selected from the group consisting of aryl, substituted aryl, heterocyclic and substituted heterocyclic and where n=0, 1 or 2,

[0026] g. S(O)_(n)-(C1-C6-alkyl), optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, where n is as previously defined,

[0027] h. S(O)_(n)-(C2-C6-alkenyl), optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, where n is as previously defined

[0028] i. S(O)_(n)-(C2-C6-alkynyl), optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, where n is as previously defined, and

[0029] j. O-M-Y, where M is

[0030] (i) absent,

[0031] (ii) —C(O)—

[0032] (iii) —C(O)N(R7)—, where R7 is as previously defined,

[0033] (iv) C1-C6-alkyl-N(R7)—, where R7 is as previously defined,

[0034] (v) C2-C6-alkenyl-N(R7)—, where R7 is as previously defined, and

[0035] (vi) C2-C6-alkynyl-N(R7)—, where R7 is as previously defined

[0036] and where Y is

[0037] (i) hydrogen

[0038] (ii) C1-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic,

[0039] (iii) C2-C6-alkenyl, optionally substituted with one or more substituents selected from the grop consisting of halogen, aryl, substituted aryl, heterocyclic and substituted hetreocyclic,

[0040] (iv) C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic,

[0041] (v) aryl,

[0042] (vi) substituted aryl,

[0043] (vii) heterocyclic, or

[0044] (viii) substituted heterocyclic,

[0045] (3) substituted or unsubstituted imidazole, arylimidazole or heteroarylimidazole,

[0046] (4) substituted or unsubstituted oxazole, aryloxazole or heteroaryloxazole,

[0047] (5) substituted or unsubstituted thioxazole, arylthioxazole or heteroarylthioxazole,

[0048] (6) substituted or unsubstituted imidazoline, arylimidazoline or heteroarylimidazoline,

[0049] (7) substituted or unsubstituted oxazoline, aryloxazoline or heteroaryloxazoline, and

[0050] (8) substituted or unsubstituted thioxazoline, arylthioxazoline and heteroarylthioxazoline,

[0051] R1 and R2 are each independently selected from the group consisting of;

[0052] (1) hydrogen,

[0053] (2) hydroxy,

[0054] (3) protected hydroxy,

[0055] (4) OC(O)—C1-C12-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic, substituted heterocyclic, O—R7 and NR7R8 where R7 and R8 are as previously defined,

[0056] (5) O—R7, where R7 is as previously defined,

[0057] (6) halogen,

[0058] (7) R1 and R2 taken together are oxo, and

[0059] (8) NR7R8, where R7 and R8 are as previously defined;

[0060] R3 is selected from the group consisting of;

[0061] (1) hydrogen,

[0062] (2) a hydroxy protecting group, and

[0063] (3) C(O)—C1-C12 alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic, substituted heterocyclic, O—R7and NR7R8 where R7 and R8 are as previously defined;

[0064] R4 is selected from the group consisting of;

[0065] (1) hydrogen,

[0066] (2) hydroxy, and

[0067] (3) O-M-Y, where M and Y are as previously defined, and

[0068] R^(p) is hydrogen or a hydroxy protecting group.

[0069] In another embodiment, the present invention provides a process for preparing novel compounds represented by Formula I wherein the groups R1, R2, R3, R4, and R^(p) are as previously defined.

DETAILED DESCRIPTION OF THE INVENTION

[0070] A first embodiment of the invention is a compound represented by Formula I as described above.

[0071] Representative compounds of the invention are those selected from the group consisting of:

[0072] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OH and R^(p)═H

[0073] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH-phenyl and R^(p)═H

[0074] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH(CH₂)₂-phenyl and R^(p)═H

[0075] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NHCH₂CHCH₂ and R^(p)=H

[0076] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NHCH₂-phenyl and R^(p)═H

[0077] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R₄═OC(O)NH-[4-NO₂-phenyl] and R^(p)═H

[0078] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R₄═OC(O)NHCH₂-[4-OCH₃-phenyl] and R^(p)═H

[0079] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH₂ and R^(p)═H

[0080] Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═OH, and R^(p)═H

[0081] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OCH₂CHCH₂ and R^(p)═H

[0082] Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═H and R^(p)═H

[0083] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═H and R^(p)═H

[0084] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3═H, R₄═OH and R^(p)═H

[0085] Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3═H, R₄═OH and R^(p)═H

[0086] Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3═H, R₄═OCH₂CHCH₂ and R^(p)=H

[0087] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3═H, R4═OCH₂CHCH₂, and R^(p)═H

[0088] Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═OCHCHCH₂-(3-quinolyl) and R^(p)═H

[0089] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OCHCHCH₂-(3-quinolyl) and R^(p)═H

[0090] Definitions

[0091] The terms “C₁-C₃-alkyl” or “C₁-C₆-alkyl” as used herein refer to saturated, straight- or branched-chain hydrocarbon radicals containing between one and three or one and six carbon atoms, respectively. Examples of C₁-C₃ alkyl radicals include methyl, ethyl, propyl and isopropyl, and examples of C₁-C₆-alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl and n-hexyl.

[0092] The term “C₁-C₆-alkoxy” as used herein refers to an C₁-C₆-alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom. Examples of C₁-C₆-alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert-butoxy, neopentoxy and n-hexoxy.

[0093] The term “C₁-C₃-alkyl-amino” as used herein refers to one or two C₁-C₃-alkyl groups, as previously defined, attached to the parent molecular moiety through a nitrogen atom. Examples of C₁-C₃-alkyl-amino include, but are not limited to methylamino, dimethylamino, ethylamino, diethylamino, and propylamino.

[0094] The term “aprotic solvent” as used herein refers to a solvent that is relatively inert to proton activity, i.e., not acting as a proton-donor. Examples include, but are not limited to, hydrocarbons, such as for example, hexane and toluene, and the like, halogenated hydrocarbons, such as, for example, methylene chloride, ethylene chloride, chloroform, and the like, heterocyclic compounds, such as, for example, tetrahydrofuran, N-methylpyrrolidinone, and the like and ethers such as for example, diethyl ether, bis-methoxymethyl ether and the like. Such compounds are well known to those skilled in the art, and it will be apparent to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of aprotic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick et al., Vol. II, in the Techniques of Chemistry Series, John Wiley & Sons, NY, 1986.

[0095] The term “aryl” as used herein refers to unsubstituted carbocyclic aromatic groups including, but not limited to, phenyl, 1- or 2-naphthyl and the like.

[0096] The terms “C₃-C₅-cycloalkyl- and C₃-C₇-cycloalkyl” as used herein refer to carbocyclic groups of 3 to 5 or 3 to 7 carbon atoms, respectively, such as for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

[0097] The term “C₁-C₃-alkyl-C₃-C₅-cycloalkyl”, as used herein refers to a C₃-C₅-cycloalkyl radical, as defined above, attached to a C₁-C₃-alkyl radical by replacement of a hydrogen atom on the latter.

[0098] The terms “halo” and “halogen” as used herein refer to an atom selected from fluorine, chlorine, bromine and iodine.

[0099] The term “heteroaryl”, as used herein, refers to a cyclic aromatic radical having from five to ten ring atoms of which one ring atom is selected from S, O and N; zero, one or two ring atoms are additional heteroatoms independently selected from S, O and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.

[0100] The term “heterocycloalkyl” as used herein, refers to a non-aromatic 5-, 6- or 7-membered ring or a bi- or tri-cyclic group comprising fused six-membered rings having between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein (i) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (ii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iii) the nitrogen heteroatom may optionally be quaternized, and (iv) any of the above heterocyclic rings may be fused to a benzene ring. Representative heterocycles include, but are not limited to, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl.

[0101] The term “heterocyclic”, as used herein, refers to heterocycloalkyl and heteroaryl. The term “substituted heterocyclic”, as used herein, refers to substituted heterocycloalkyl and substituted heteroaryl.

[0102] The term “substituted aryl” as used herein refers to an aryl group as defined herein substituted by independent replacement of one or more of the hydrogen atoms therein with F, Cl, Br, I, OH, NO₂, CN, C(O)—C₁-C₆-alkyl, C(O)-aryl, C(O)-heteroaryl, CO₂-alkyl, CO₂-aryl, CO₂-heteroaryl, CONH₂, CONH—C₁-C₆-alkyl, CONH-aryl, CONH-heteroaryl, OC(O)—C₁-C₆-alkyl, OC(O)-aryl, OC(O)-heteroaryl, OCO₂-alkyl, OCO₂-aryl, OCO₂-heteroaryl, OCONH₂, OCONH—C₁-C₆-alkyl, OCONH-aryl, OCONH-heteroaryl, NHC(O)-C₁-C₆-alkyl, NHC(O)-aryl, NHC(O)-heteroaryl, NHCO₂-alkyl, NHCO₂-aryl, NHCO₂-heteroaryl, NHCONH₂, NHCONH—C₁-C₆-alkyl, NHCONH-aryl, NHCONH-heteroaryl, SO₂-C₁-C₆-alkyl, SO₂-aryl, SO₂-heteroaryl, SO₂NH₂, SO₂NH—C₁-C₆-alkyl, SO₂NH-aryl, SO₂NH-heteroaryl, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, CF₃, CH₂CF₃, CHCl₂, CH₂OH, CH₂CH₂OH, CH₂NH₂, CH₂SO₂CH₃, aryl, heteroaryl, benzyl, benzyloxy, aryloxy, heteroaryloxy, C₁-C₆-alkoxy, methoxymethoxy, methoxyethoxy, amino, benzylamino, arylamino, heteroarylamino, C₁-C₃-alkyl-amino, thio, aryl-thio, heteroarylthio, benzyl-thio, C₁-C₆-alkyl-thio, or methylthiomethyl.

[0103] The term “substituted heteroaryl” as used herein refers to a heteroaryl group as defined herein substituted by independent replacement of one or more of the hydrogen atoms therein with F, Cl, Br, I, OH, NO₂, CN, C(O)—C₁-C₆-alkyl, C(O)-aryl, C(O)-heteroaryl, CO₂-alkyl, CO₂-aryl, CO₂-heteroaryl, CONH₂, CONH—C₁-C₆-alkyl, CONH-aryl, CONH-heteroaryl, OC(O)—C₁-C₆-alkyl, OC(O)-aryl, OC(O)-heteroaryl, OCO₂-alkyl, OCO₂-aryl, OCO₂-heteroaryl, OCONH₂, OCONH—C₁-C₆-alkyl, OCONH-aryl, OCONH-heteroaryl, NHC(O)—C₁-C₆-alkyl, NHC(O)-aryl, NHC(O)-heteroaryl, NHCO₂-alkyl, NHCO₂-aryl, NHCO₂-heteroaryl, NHCONH₂, NHCONH—C₁-C₆-alkyl, NHCONH-aryl, NHCONH-heteroaryl, SO₂—C₁-C₆-alkyl, SO₂-aryl, SO₂-heteroaryl, SO₂NH₂, SO₂NH—C₁-C₆-alkyl, SO₂NH-aryl, SO₂NH-heteroaryl, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, CF₃, CH₂CF₃, CHCl₂, CH₂OH, CH₂CH₂OH, CH₂NH₂, CH₂SO₂CH₃, aryl, heteroaryl, benzyl, benzyloxy, aryloxy, heteroaryloxy, C₁-C₆-alkoxy, methoxymethoxy, methoxyethoxy, amino, benzylamino, arylamino, heteroarylamino, C₁-C₃-alkyl-amino, thio, aryl-thio, heteroarylthio, benzyl-thio, C₁-C₆-alkyl-thio, or methylthiomethyl.

[0104] The term “substituted heterocycloalkyl” as used herein, refers to a heterocycloalkyl group, as defined above, substituted by independent replacement of one or more of the hydrogen atoms therein with F, Cl, Br, I, OH, NO₂, CN, C(O)—C₁-C₆-alkyl, C(O)-aryl, C(O)-heteroaryl, CO₂-alkyl, CO₂-aryl, CO₂-heteroaryl, CONH₂, CONH—C₁-C₆-alkyl, CONH-aryl, CONH-heteroaryl, OC(O)—C₁-C₆-alkyl, OC(O)-aryl, OC(O)-heteroaryl, OCO₂-alkyl, OCO₂-aryl, OCO₂-heteroaryl, OCONH₂, OCONH—C₁-C₆-alkyl, OCONH-aryl, OCONH-heteroaryl, NHC(O)—C₁-C₆-alkyl, NHC(O)-aryl, NHC(O)-heteroaryl, NHCO₂-alkyl, NHCO₂-aryl, NHCO₂-heteroaryl, NHCONH₂, NHCONH—C₁-C₆-alkyl, NHCONH-aryl, NHCONH-heteroaryl, SO₂-C₁-C₆-alkyl, SO₂-aryl, SO₂-heteroaryl, SO₂NH₂, SO₂NH—C₁-C₆-alkyl, SO₂NH-aryl, SO₂NH-heteroaryl, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, CF₃, CH₂CF₃, CHCl₂, CH₂OH, CH₂CH₂OH, CH₂NH₂, CH₂SO₂CH₃, aryl, heteroaryl, benzyl, benzyloxy, aryloxy, heteroaryloxy, C₁-C₆-alkoxy, methoxymethoxy, methoxyethoxy, amino, benzylamino, arylamino, heteroarylamino, C₁-C₃-alkyl-amino, thio, aryl-thio, heteroarylthio, benzyl-thio, C₁-C₆-alkyl-thio, or methylthiomethyl.

[0105] The term “substituted cycloalkyl”, as used herein, refers to a C₃-C₇ cycloalkyl group, as defined above, substituted by independent replacement of one or more of the hydrogen atoms therein with F, Cl, Br, I, OH, NO₂, CN, C(O)—C₁-C₆-alkyl, C(O)-aryl, C(O)-heteroaryl, CO₂-alkyl, CO₂-aryl, CO₂-heteroaryl, CONH₂, CONH—C₁-C₆-alkyl, CONH-aryl, CONH-heteroaryl, OC(O)—C₁-C₆-alkyl, OC(O)-aryl, OC(O)-heteroaryl, OCO₂-alkyl, OCO₂-aryl, OCO₂-heteroaryl, OCONH₂, OCONH—C₁-C₆-alkyl, OCONH-aryl, OCONH-heteroaryl, NHC(O)—C₁-C₆-alkyl, NHC(O)-aryl, NHC(O)-heteroaryl, NHCO₂-alkyl, NHCO₂-aryl, NHCO₂-heteroaryl, NHCONH₂, NHCONH—C₁-C₆-alkyl, NHCONH-aryl, NHCONH-heteroaryl, SO₂—C₁-C₆-alkyl, SO₂-aryl, SO₂-heteroaryl, SO₂NH₂, SO₂NH—C₁-C₆-alkyl, SO₂NH-aryl, SO₂NH-heteroaryl, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, CF₃, CH₂CF₃, CHCl₂, CH₂OH, CH₂CH₂OH, CH₂NH₂, CH₂SO₂CH₃, aryl, heteroaryl, benzyl, benzyloxy, aryloxy, heteroaryloxy, C₁-C₆-alkoxy, methoxymethoxy, methoxyethoxy, amino, benzylamino, arylamino, heteroarylamino, C₁-C₃-alkyl-amino, thio, aryl-thio, heteroarylthio, benzyl-thio, C₁-C₆-alkyl-thio, or methylthiomethyl

[0106] “Hydroxy-protecting group”, as used herein, refers to an easily removable group which is known in the art to protect a hydroxyl group against undesirable reaction during synthetic procedures and to be selectively removable. The use of hydroxy-protecting groups is well known in the art for protecting groups against undesirable reactions during a synthetic procedure and many such protecting groups are known. See, for example, T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons, New York (1991). Examples of hydroxy-protecting groups include, but are not limited to, methylthiomethyl, tert-dimethylsilyl, tert-butyldiphenylsilyl, acyl substituted with an aromatic group and the like.

[0107] The term “protected-hydroxy” refers to a hydroxy group protected with a hydroxy protecting group, as defined above, including benzoyl, acetyl, trimethylsilyl, triethylsilyl, methoxymethyl groups, for example.

[0108] “Aldehyde-protecting group”, as used herein, refers to an easily removable group which is known to protect an aldehyde group against undesirable reaction during synthetic procedures and to be selectively removable. The use of aldehyde-protecting groups is well known in the art for protecting aldehyde groups against undesirable reactions during a synthetic procedure and many such protecting groups are known. See, for example, T. H. Greene and P. G, M, Wuts, Protective Groups in Organic Synthesis, op. cit. Examples of aldehyde-protecting groups include, but are not limited to, acetals, ketals, O-substituted cyanohydrins, substituted hydrazones, imines and the like.

[0109] The term “protected aldehyde” refers to an aldehyde group protected with an aldehyde protecting group, as defined above, including dimethyl acetyl, 1,3-dioxolane, 1,3-dioxane and the like.

[0110] The term “protogenic organic solvent” as used herein refers to a solvent that tends to provide protons, such as an alcohol, for example, methanol, ethanol, propanol, isopropanol, butanol, t-butanol, and the like. Such solvents are well known to those skilled in the art, and it will be apparent to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of protogenic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick et al., Vol. II, in the Techniques of Chemistry Series, John Wiley & Sons, NY, 1986.

[0111] Numerous asymmetric centers may exist in the compounds of the present invention. Except where otherwise noted, the present invention contemplates the various stereoisomers and mixtures thereof. Accordingly, whenever a bond is represented by a wavy line, it is intended that a mixture of stereo-orientations or an individual isomer of assigned or unassigned orientation may be present. Further, in those cases where a bond between carbon atoms of the macrolide is a double bond both the cis and trans forms are within the scope of the invention described in this application.

[0112] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977), incorporated herein by reference. The salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptalble salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

[0113] As used herein, the term “pharmaceutically acceptable ester” refers to esters which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.

[0114] The term “pharmaceutically acceptable prodrugs” as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, commensurate with a reasonable risk/benefit ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term “prodrug” refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood. A thorough discussion is provided in T. compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Prodrugs as Novel delivery Systems, Vol. 14 of the A.C.S. Symposium Series and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated by reference herein.

[0115] Antibacterial Activity

[0116] Susceptibility tests can be used to quantitatively measure the in vitro activity of an antimicrobial agent against a given bacterial isolate. Compounds were tested for in vitro antibacterial activity by a microdilution method. Minimal Inhibitory Concentration (MIC) was determined in 96 well microtiter plates utilizing the appropriate Mueller Hinton Broth medium (CAMHB) for the observed bacterial isolate. Antimicrobial agents were serially diluted (2-fold) in DMSO to produce a concentration range of 64 ug/ml to 0.0625 ug/ml. The diluted compounds (2 ul/well) were then transferred into sterile, uninoculated CAMHB 0.2 mL) by use of a 96 fixed tip-pipetting station. The inoculum for each bacterial strain was standardized to 5×10⁵ CFU/mL by optical comparison to a 0.5 McFarland turbidity standard. The plates were inoculated with 10 ul/well of adjusted bacterial inoculum. The 96 well plates were covered and incubated at 35 +/−2° C. for 24 hours in ambient air environment. Following incubation, plate wells were visually examined by Optical Density measurement for the presence of growth (turbidity). The lowest concentration of an antimicrobial agent at which no visible growth occurs was defined as the MIC. The compounds of the invention generally demonstrated an MIC in the range of from 0.06 to 64 μg/ml.

[0117] Pharmaceutical Compositions

[0118] The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers. As used herein, the term “pharmaceutically acceptable carrier” means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, or as an oral or nasal spray.

[0119] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0120] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

[0121] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0122] In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides) Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

[0123] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

[0124] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[0125] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

[0126] The solid dosage forms of tablets, powders, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition whereby they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

[0127] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.

[0128] The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0129] Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

[0130] The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

[0131] Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.

[0132] Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

[0133] According to the methods of treatment of the present invention, bacterial infections are treated or prevented in a patient such as a human or lower mammal by administering to the patient a therapeutically effective amount of a compound of the invention, in such amounts and for such time as is necessary to achieve the desired result. By a “therapeutically effective amount” of a compound of the invention is meant a sufficient amount of the compound to treat bacterial infections, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.

[0134] The total daily dose of the compounds of this invention administered to a human or other mammal in single or in divided doses can be in amounts, for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight. Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose. In general, treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of this invention per day in single or multiple doses.

[0135] Abbreviations

[0136] Abbreviations which have been used in the descriptions of the scheme and the examples that follow are: AIBN for azobisisobutyronitrile; Bu3SnH for tributyltin hydride; CDI for carbonyldiimidazole; DBU for 1,8-diazabicyclo[5.4.0]undec-7-ene; DEAD for diethylazodicarboxylate; DMF for dimethyl formamide; DPPA for diphenylphosphoryl azide; EtOAc for ethyl acetate; MeOH for methanol; NaN(TMS)₂ for sodium bis(trimethylsilyl)amide; NMO for N-methylmorpholine N-oxide; TEA for triethylamine; THF for tetrahydrofuran; TPP for triphenylphosphine; DMAP for 4-N,N-dimethylamino-pyridine; TFA for trifluoroacetic acid, KHMDS for potassium bis(trimethylsilyl)amide, Ac for acetyl and Bz for benzoyl.

[0137] Synthetic Methods

[0138] The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes which are illustrative of the methods by which the compounds of the invention may be prepared. The groups A, R1, R2, R3, R4, and R^(p) are as defined previously unless otherwise noted below.

[0139] One process of the invention for the preparation of the compounds of Formula I comprises reacting a protected josamycin derivative (compound 1 of Scheme 1, R3=acetyl, R5=CH₂CH(CH₃)₂ and R^(p)=acetyl or benzoyl) with dilute aqueous acids (0.1-5N) such as hydrochloric acid, sulfuric acid, trifluoroacetic acid, acetic acid and the like, optionally in an organic solvent such as acetone, acetonitrile, methanol, ethanol or the like, or combinations thereof, at from 0° C. to 70° C. for 1-24 hours to provide compound 2. Compound 2 is treated with an isocyanate reagent in an aprotic solvent such as methylene chloride, ethylene chloride, THF, chloroform, DMF, acetonitrile or the like at from 0° C. to 50° C. for 1-48 hours to provide compound 3 which further reacts with methanol at from room temperature to refluxing temperature to remove the hydroxy protecting group at the 2′-position where OR^(p) is an ester or a silyl ether.

[0140] In another process of the invention for the preparation of the compounds of Formula I, compound 1 of Scheme 2 is treated with acetyl chloride, hydrochloric acid, acetic acid or the like to provide a pH of 1-4 in an alcoholic solvent such as methanol, ethanol, ethylene glycol or the like to provide compound 5 with the cleavage of the mycarosyl sugar while protecting the C20-aldehyde as an acetal directly. Compound 5 is alkylated with an alkylating agent such as an alkyl halide, alkyl sulphonate, propargyl halide, allyl halide, benzylic halide or the like in the presence of a base such as sodium hydride, potassium hydride, potassium tert-butoxide, potassium hydroxide, KHMDS, or the like in an aprotic solvent such as THF, DMSO, DMF, dioxane, or the like or mixtures there of at from −20° C. to 60° C. to provide compound 6 which can be deprotected with aqueous acid followed by methanolysis to provide compound 7.

[0141] In yet another process of the invention for the preparation of the compounds of Formula I, compound 5 of Scheme 2 is reacted with an allyl bromide or propargyl bromide as described above in Scheme 3 to provide compound 6a. Compound 6a is treated with an aryl halide or aryl triflate in the presence of a palladium catalyst [Pd(0) or Pd(II)] to provide compound 6c: (See (a) Heck, Palladium Reagents in Organic Synthesis, Academic Press: New York, 1985, Chapter 1; (b) Sonogashira, Comprehensive Organic Synthesis, Volume 3, Chapters 2,4; (c) Sonogashira, Synthesis 1977, 777.). Alternatively, compound 6a can undergo a cross metathesis reaction with vinylaromatic derivatives using ruthenium catalysts (see (a) J. Org. Chem. 2000, 65, 2204-2207; (b) Reviews: Synlett. 1999, 2, 267; (c) Reviews: Ivin, K. J.; Mol, J. C. Olefin Metathesis and Metathesis Polymerization, 2^(nd) ed.; Academic Press: New York, 1997; (d) J. Org. Chem. 1999, 64, 4798-4816; (e) Angew. Chem., Int. Ed. Engl. 1997, 36, 2036-2056; (f) Tetrahedron 1998, 54, 4413-4450). Alternatively, the propargyl group of compound 6a is reduced with a variety of borane reagents to give vinyl boronic acid 6b for further palladium catalyzed Suzuki coupling reactions to provide compound 6c (see (a) Suzuki, Chemical Reviews, 1995, 95, 2457; (b) Suzuki, Pure & Appl. Chem. 1991, 63, 419).

[0142] In yet another process of the invention for the preparation of the compounds of Formula I, compound 5 of Scheme 2 is reacted with a sulphonyl halide such as methanesulfonyl chloride, toluenesulfonyl chloride, benzylsufonyl chloride and the like in an aprotic solvent such as pyridine, dichloromethane, dichloroethane, THF, DMF and the like optionally in the presence of a base such as triethyl amine, diisopropyl ethyl amine and the like at −78° C. to room temperature to provide the 4′-OSO2R′ intermediate which further is treated with NaI, KI, tetrabutyl ammonium iodide and the like in an aprotic solvents such as acetone, butanone, DMF, dioxane, and the like at from room temperature to 100° C. to provide the 4′-iodo intermediate, compound 8 (Scheme 4). The iodo functionality of compound 8 is removed by various reduction methods such as using tributyl tin hydride in the presence of AIBN in an organic solvent such as benzene, toluene, and the like or hydrogenolysis using Raney nickel in the presence of hydrogen in an organic solvent such as methanol, ethanol, ethyl acetate and the like to provide 4′-deoxy leucomycin derivatives, compound 9. Compound 9 can be converted to compound 10 via hydrolysis and methanolysis to deprotect the protecting groups as described earlier.

EXAMPLES

[0143] The procedures described above for preparing the compounds of Formula I of the present invention will be better understood in connection with the following examples which are intended to be illustrative only of, and not limiting of the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation, those relating to the chemical structures, substituents, derivatives, syntheses, formulations and/or methods of the invention may be made without departing from the spirit of the invention and the scope of the appended claims.

Example 1

[0144] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OH and R^(p)═H

[0145] Step 1a. Compound 1 of Scheme 1: R3=acetyl, R5═CH₂CH(CH₃)₂ and R^(p)=benzoyl

[0146] A solution of Josamycin (3 g, 3.6 mmol) and benzoic anhydride (2.6 g, 11 mmol) in pyridine (10 mL) was stirred for 16 hours at room temperature. The solution was concentrated under vacuum, diluted with dichloromethane, washed with saturated aqueous NaHCO₃ and dried over anhydrous Na₂SO₄. The solvent was concentrated under vacuum and the residue was purified on a silica gel column (eluting with ethyl acetate:hexane/20:80,and increasing to 60:40) to provide the title compound (2.6 g, 77% yield).

[0147] MS (ESI) m/z 930 (M+H)⁺.

[0148] Step 1b. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OH and R^(p)=benzoyl

[0149] The compound from step 1a (2 g, 1.55 mmol) in 0.3 N aqueous HCl (50 mL) was stirred at room temperature for 16 hours. To the mixture was added saturated aqueous NaHCO₃ and extracted with dichloromethane. The organic solution was dried over anhydrous Na₂SO₄ and concentrated under vacuum. The residue was purified by chromatography on a silica gel column (eluting with ethyl acetate:hexane:triethyl amine/60:40:1) to provide the title compound (1.45 g, 96%) as a white solid.

[0150] MS (ESI) m/z 702 (M+H)⁺.

[0151]³C-NMR (100 MHz, CDCl₃): δ203.1, 200.6, 170.4, 169.6, 164.3, 143.8,139.9, 133.2, 132.5, 129.8, 129.6, 128.4, 122.4, 100.1, 84.8, 75.6, 72.8, 70.7, 69.2, 69.0, 68.3, 62.1, 60.3, 44.1, 42.6, 41.4, 40.4, 36.5, 31.5, 30.5, 22.3, 21.1, 20.9, 20.3, 17.7, 17.3, 14.1.

[0152] Step 1c. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OH and R^(p)═H

[0153] A solution of the compound from step 1b (80 mg, 0.11 mmol) in methanol was refluxed for 16 hours. The solvent was evaporated under vacuum. Purification on silica gel column (eluting with ethyl acetate:hexane:triethyl amine/80:20:1) gave the title compound (46 mg, 68%) as a white solid.

[0154] MS (ESI) m/z 598 (M+H)⁺.

[0155]¹³C-NMR (100 MHz, CDCl₃): δ202.9, 200.8, 170.6, 170.0, 144.1, 140.3, 132.5, 122.2, 104.1, 84.8, 77.9, 73.2, 70.9, 70.8, 70.0, 69.1, 68.3, 62.4, 44.2, 41.7, 40.7, 36.8, 30.8, 29.6, 21.2, 20.5, 17.8, 17.4.

Example 2

[0156] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH-phenyl and R^(p)═H

[0157] Step 2a. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH-phenyl and R^(p)=benzoyl

[0158] To a solution of the compound from step 1b (0.14 g, 0.20 mmol) and triethyl amine (0.22 mL, 1.6 mmol) in dichloromethane (2 mL) was added phenyl isocyanate (0.086 mL, 0.8 mmol). The mixture was stirred for 5 hours at room temperature, diluted with dichloromethane, washed with saturated aqueous NaHCO₃, and dried over anhydrous Na₂SO₄. The solvent was evaporated to give the title compound (0.16 g, 100%).

[0159] MS (ESI) m/z 821 (M+H)⁺.

[0160] Step 2b. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH-phenyl and R^(p)═H

[0161] A solution of the compound from step 2a (0.16 g, 0.2 mmol) in methanol (20 mL) was refluxed for 16 hours. The solvent was evaporated under vacuum. Purification on silica gel column (eluting with ethyl acetate:hexane:triethyl amine/60:40:1) gave the title compound (57 mg, 40%) as a white solid.

[0162] MS (ESI) m/z 717 (M+H)⁺.

[0163]¹³C-NMR (100 MHz, CDCl₃): δ203.0, 200.8, 170.5, 169.8, 144.1, 140.0, 137.4, 132.7, 129.1, 123.8, 122.2, 118.6, 102.9, 84.8, 71.4, 69.2, 69.1, 68.4, 62.6, 48.7, 44.3, 42.7, 41.3, 40.6, 36.7, 32.2, 30.5, 29.7, 21.2, 20.4, 17.4, 16.9.

Example 3

[0164] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH(CH₂)₂-phenyl and R^(p)═H

[0165] The product from step 1b was processed as described in steps 2a and 2b of Example 2, substituting phenethyl isocyanate for phenyl isocyanate to provide the title compound (68.2 mg, 46%) as a white solid.

[0166] MS (ESI) m/z 745 (M+H)⁺.

[0167]¹³C-NMR (100 MHz, CDCl₃): δ203.0, 200.7, 170.5, 170.0, 154.8, 144.0, 140.0, 138.4, 132.7, 128.7, 128.6, 126.5, 122.2, 102.9, 84.8, 71.7,71.5, 69.2, 69.0, 68.4, 62.5, 44.3, 42.7, 42.1, 41.2, 40.6, 36.6, 36.1, 32.1, 30.4, 29.6, 21.1, 20.4, 17.4, 16.8.

Example 4

[0168] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NHCH₂CHCH₂ and R^(p)═H

[0169] The product from step 1b was processed as described in steps 2a and 2b of Example 2, substituting allyl isocyanate for phenyl isocyanate and cooling at 0° C. to provide the title compound (45.5 mg, 34%) as a white solid.

[0170] MS (ESI) m/z 681 (M+H)⁺.

[0171]¹³C-NMR (100 MHz, CDCl₃): δ203.2, 200.1, 170.5, 169.8, 154.8, 144.0, 140.0, 135.4, 134.2, 132.7, 122.2, 116.0, 115.6, 102.9, 84.8, 71.6, 69.2, 69.0, 68.4, 62.5, 44.3, 43.4, 43.0, 42.7, 41.2, 40.6, 36.6, 30.4, 21.2, 20.4, 17.4, 16.9.

Example 5

[0172] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NHCH₉-phenyl and R^(p)═H

[0173] The product from step 1b was processed as described in steps 2a and 2b of Example 2, substituting benzyl isocyanate for phenyl isocyanate to provide the title compound (67 mg, 46%) as a white solid.

[0174] MS (ESI) m/z 731 (M+H)⁺.

[0175]¹³C-NMR (100 MHz, CDCl₃): δ203.3, 201.0, 170.7, 170.1, 155.3, 144.3, 140.2, 138.4, 132.9, 128.9, 127.8, 127.6, 122.5, 103.1, 85.0, 72.3, 71.8, 69.5, 69.4, 69.3, 68.7, 62.8, 45.4, 44.5, 43.0, 41.4, 40.8, 36.9, 32.3, 30.7, 21.4, 20.7, 17.6, 17.1.

Example 6

[0176] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R₄═OC(O)NH-[4-NO₂-phenyl] and R^(p)═H

[0177] Step 6a. Compound 2 of Scheme 1: R3=acetyl, and R^(p)=acetyl.

[0178] A solution of compound 1 of Scheme 1, (wherein R3=acetyl, R5=CH₂CH(CH₃)₂ and R^(p)=acetyl) (3 g, 3.46 mmol) in 0.3 N aqueous HCl (70 mL) was stirred at room temperature for 16 hours. The mixture was neutralized with saturated aqueous NaHCO₃ and extracted with dichloromethane. The organic solution was dried over anhydrous Na₂SO₄ and concentrated under vacuum. The residue was purified on silica gel column (eluting with ethyl acetate:hexane:triethylamine/60:40:1) to provide the title compound (1.6 g, 79%) as a white solid.

[0179] MS (ESI) m/z 640 (M+H)⁺.

[0180] Step 6b. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH-[4-NO₂-phenyl] and R^(p)=acetyl

[0181] To a solution of the compound from step 6a (0.128 g, 0.20 mmol) and triethyl amine (0.167 mL, 1.20 mmol) in dichloromethane (10 mL) was added 4-nitrophenyl isocyanate (101 mg, 0.60 mmol). The mixture was stirred for 16 hours at room temperature, diluted with dichloromethane, washed with saturated aqueous NaHCO₃, and dried over anhydrous Na₂SO₄. The solvent was evaporated to give the title compound (0.16 g, 100%).

[0182] MS (ESI) m/z 804 (M+H)⁺.

[0183] Step 6c. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH-[4-NO₂-phenyl] and R^(p)═H

[0184] A solution of the compound from step 6b (0.16 g, 0.2 mmol) in methanol (20 mL) was stirred for 16 hours at room temperature. The solvent was evaporated under vacuum. Purification on silica gel column (eluting with dichloromethane:methanol:ammonium hydroxide/90:10:1) gave the title compound (90 mg, 60%) as a yellow solid.

[0185] MS (ESI) m/z 762 (M+H)⁺.

[0186]¹³C-NMR (100 MHz, CDCl₃): δ203.3, 200.8, 170.6, 169.9, 153.3, 151.5, 144.3, 143.9, 143.5, 143.2, 142.9, 140.3, 132.6, 125,2, 122.1, 117.9, 117.7, 103.0, 71.2, 69.3, 69.1, 68.9, 62.6, 52.8, 41.3, 21.2, 20.4, 17.4, 17.0.

Example 7

[0187] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R₄═OC(O)NHCH₂-[4-OCH₃-phenyl] and R^(p)═H

[0188] The product from step 6a was processed as described in steps 6b and 6c of Example 6, substituting 4-methoxybenzyl isocyanate for 4-nitrophenyl isocyanate to provide the title compound (100 mg, 66%) as a white solid.

[0189] MS (ESI) m/z 761(M+H)⁺.

[0190]¹³C-NMR (100 MHz, CDCl₃): δ203.0, 200.7, 170.5, 169.9, 159.1, 154.9, 144.1, 139.9, 132.7, 128.8, 128.7, 122.3, 114.1, 114.0, 113.9, 102.9, 84.8, 69.3, 69.2, 69.1, 68.4, 62.5, 55.3, 44.6, 44.3, 44.0, 41.2, 40.6, 30.5, 21.2, 20.4, 17.4, 16.9.

Example 8

[0191] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl R4═OC(O)NH₂ and R^(p)═H

[0192] Step 8a. Compound of Formula I: A=CHO R1 and R2 taken together=O, R3=acetyl, R4=OC(O)NHC(O)CCl₃ and R^(p)═acetyl

[0193] To a solution of the compound from step 6a (0.128 g, 0.20 mmol) in dichloromethane (2 mL) was added trichloroacetyl isocyanate (0.036 mL, 0.30 mmol). The mixture was stirred for 1 hour at 0° C., quenched with isopropanol (1 mL) and stirred for 5 minutes. The solvent was evaporated under vacuum to give the crude title compound (0.16 g, 100%).

[0194] MS (ESI) m/z 827M+H)⁺.

[0195] Step 8b. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH₂ and R^(p)═acetyl

[0196] A solution of the compound from step 8a (0.13 g, 0.16 mmol) in methanol/saturated aqueous NaHCO₃ (5 mL/0.5 mL) was stirred for 30 minutes at room temperature. The mixture was diluted with saturated aqueous NaHCO₃ and extracted with dichloromethane. The organic solution was dried over anhydrous Na₂SO₄ and concentrated under vacuum to provide the crude desired product (0.11 g, 100%).

[0197] MS (ESI) m/z 683 (M+H)⁺.

[0198] Step 8c. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH₂ and R^(p)═H

[0199] A solution of the compound from step 8b (0.11 g, 0.2 mmol) in methanol (8 mL) was stirred for 16 hours at room temperature. The solvent was evaporated under vacuum. Purification on silica gel column (eluting with dichloromethane:methanol:ammonium hydroxide/95:5:1) gave the title compound (55 mg, 56%) as a white solid.

[0200] MS (ESI) m/z 641 (M+H)⁺.

[0201]³C-NMR (100 MHz, CDCl₃): δ203.1, 200.1, 170.5, 169.9, 155.2, 144.1, 140.0, 132.7, 122.2, 102.9, 84.8, 72.2, 71.5, 69.2, 69.1, 68.4, 62.5, 44.3, 42.7, 41.2, 40.6, 36.6, 32.1, 30.4, 21.2, 20.4, 17.4, 16.8.

Example 9

[0202] Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═OH and R^(p)═H Step 9a. Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═OH and R^(p)=acetyl

[0203] To a solution of compound 1 of Scheme 1 (R3=acetyl, R5=CH₂CH(CH₃)₂ and R^(p)=acetyl) (10 g, 11.5 mmol) in methanol (100 mL) was added acetyl chloride at 0° C. The pH of the solution was adjusted to pH 2-3. The mixture was stirred for 16 hours, neutralized with sodium bicarbonate, and concentrated. Purification onsilica gel column (eluting with ethyl acetate:hexane:triethyl amine/80:20:1) gave the title compound (5.6 g, 74%) as a white solid.

[0204] MS (ESI) m/z 686 (M+H)⁺.

[0205] Step 9b. Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═OH and R^(p)═H

[0206] A solution of the compound from step 9b (2.1 g, 3.0 mmol) in methanol (20 mL) was stirred for 16 hours at room temperature. The solvent was evaporated under vacuum to give the title compound (1.9 g, 100%) as a white solid.

[0207] MS (ESI) m/z 644 (M+H)⁺.

[0208]¹³C-NMR (100 MHz, CDCl₃): δ203.5, 170.2, 169.9, 143.9, 140.2, 132.8, 122.7, 104.8, 101.3, 85.2, 78.8, 73.6, 70.7, 70.3, 69.4, 69.3, 68.8, 62.5, 62.4, 54.3, 48.1, 44.3, 41.9, 40.6, 37.1, 33.6, 32.7, 30.4, 21.2, 20.6, 18.1, 17.9.

Example 10

[0209] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OCH₂CHCH₂ and R^(p)═H

[0210] Step 10a. Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═OCH₂CHCH₂ and R^(p)=acetyl

[0211] A solution of the compound from step 9a ( 0.343 g, 0.5 mmol), t-butyl allylcarbonate (0.237 g, 1.5 mmol), 1,4-bis(diphenylphosphino)butane (42.6 mg, 0.1 mmol), tris(dibenzylideneacetone)dipalladium (45.8 mg, 0.05 mmol) in degassed tetrahydrofuran (5 mL) was heated at 68° C. for 2 hours and concentrated. Purification on a silica gel column (eluting with ethyl acetate:hexane/20:80 and increasing to 50:50) gave the title compound (300 mg, 83%) as a white solid.

[0212] MS (ESI) m/z 726 (M+H)⁺.

[0213]¹³C-NMR (100 MHz, CDCl₃): δ204.0, 170.2, 169.9, 169.2, 143.7, 139.8, 135.1, 133.0, 122.7, 117.2, 100.4, 85.7, 79.4, 75.5, 73.3, 72.4, 71.1, 69.3, 68.9, 68.8, 62.2, 54.2, 46.8, 44.3, 41.7, 40.4, 36.9, 33.1, 32.0, 29.4, 21.7, 21.6, 20.6, 18.2, 17.9.

[0214] Step 10b. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4=OCH₂CHCH₂ and R^(p)=acetyl

[0215] To a solution of the compound from step 10a (130 mg, 0.18 mmol) in acetonitrile (2 mL) was added water (10 mL) and TFA (0.04 mL, 0.52 mmol). The mixture was stirred for 16 hours at room temperature, diluted with saturated aqueous NaHCO₃ and extracted with dichloromethane. The solvent was evaporated under vacuum. Purification on silica gel column (eluting with ethyl acetate:hexane/50:50) gave the desire product (73 mg, 61%) as a white solid.

[0216] MS (ESI) m/z 680 (M+H)⁺.

[0217] Step 10c. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OCH₂CHCH₂ and R^(p)═H

[0218] A solution of the compound from step 10b (73 mg, 0.11 mmol) in methanol (2 mL) was stirred for 16 hours at room temperature. The solvent was evaporated under vacuum to give the title compound (65 mg, 95%) as a white solid.

[0219] MS (ESI) m/z 638 (M+H)⁺.

[0220]¹³C-NMR (100 MHz, CDCl₃): δ203.2, 200.1, 170.7, 170.0, 144.2, 140.2, 134.5, 132.8, 103.1, 85.0, 79.9, 73.1, 72.5, 70.3, 69.7, 69.2, 68.7, 62.7, 44.5, 43.0, 41.7, 40.8, 36.9, 32.4, 21.3, 20.6, 18.2, 17.6.

Example 11

[0221] Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═H and R^(p)═H

[0222] Step 11a: Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3═Ac, R4═OS(O)₂CH₂-phenyl and R^(p)═H

[0223] To a cold solution of the compound from step 9b (1.29 g, 2.0 mmol) in dry pyridine (15 mL) was added phenylmethanesulfonyl chloride (0.53 g, 2.8 mmol). The mixture was stirred for 3 hours at −40° C. Water (0.5 mL) was added and the solution was warmed to room temperature. The reaction mixture was concentrated and extracted with dichloromethane. The organic solution was washed with saturated aqueous NaHCO₃, dried over anhydrous MgSO₄ and concentrated under vacuum to give the desired compound (1.49 g, 93%) as a yellow solid.

[0224] MS (ESI) m/z 798 (M+H)⁺.

[0225] Step 11b: Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═I and R^(p)═H

[0226] To a solution of the compound from step 11a (1.0 g, 1.25 mmol) in dry 2-butanone (15 mL) was added NaI (0.38 g, 2.5 mmol) and the mixture was stirred under nitrogen for 1 hour at 80° C. Concentration gave a residue, which was extracted with ethyl acetate. The organic solution was washed with 0.1 M aqueous Na₂S₂O₃ and water, dried over anhydrous MgSO₄ and concentrated. The residue was chromatographed with acetone-hexane (2:7) to provide the title compound (0.80 g, 85%) as a white solid.

[0227] MS (ESI) m/z 754 (M+H)⁺.

[0228] Step 11c. Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═H and R^(p)═H

[0229] To a solution of the compound from step 11b (0.42 g, 0.56 mmol) in dry benzene (7 mL) was added Bu₃SnH (487 mg, 1.67 mmol) and AIBN (18 mg, 0.1 mmol). The solution was heated under nitrogen for 2 hours at 80° C. Concentration gave a residue, which was chromatograhed by successive use of hexane-acetone (3:1), dichloromethane, dichloromethane-methanol-28% aqueous NH₃ (10:1:0.1) to provide the title compound (130 mg, 37%) as a white solid.

[0230] MS (ESI) m/z 628 (M+H)⁺.

[0231]¹³C-NMR (100 MHz, CDCl₃): δ203.9, 170.4, 170.0, 143.9, 140.1, 132.9, 122.6, 103.6, 100.9, 85.3, 70.4, 69.2, 68.9, 65.8, 62.6, 54.2, 47.6, 44.5, 40.6, 36.9, 33.6, 32.2, 29.9, 29.5, 29.3, 26.8, 21.3, 21.2, 17.9, 16.6.

Example 12

[0232] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R₄═H and R^(p)═H

[0233] To a solution of the compound from Example 11 (130 mg, 0.21 mmol) in acetonitrile (2 mL) was added water (10 mL) and TFA (0.04 mL, 0.52 mmol). The mixture was stirred for 16 hours at room temperature, diluted with saturated aqueous NaHCO₃ and extracted with dichloromethane. The solvent was evaporated under vacuum. Purification on silica gel column (eluting with dichloromethane: methanol: 28% aqueous NH₃/10:1:0.1) gave the title compound (72 mg, 60%) as a white solid.

[0234] MS (ESI) m/z 582 (M+H)⁺.

[0235]¹³C-NMR (100 MHz, CDCl₃): δ203.9, 201.1, 170.8, 170.1, 144.2, 140.2, 132.9, 122.4, 103.8, 85.2, 70.3, 69.5, 69.2, 68.7, 65.8, 62.7, 44.6, 42.9, 40.8, 40.4, 36.9, 32.3, 30.7, 29.9, 28.4, 21.4, 21.2, 20.7, 17.6.

Example 13

[0236] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3═H, R₄═OH and R^(p)═H

[0237] Step 13a: Compound 1 of Scheme 1: R3═H, R5═CH₂CH₂CH₃ and R^(p)═H

[0238] A solution of CrO₃ (20 g, 0.2 mol) in H₂O (20 mL) was added dropwise over 20 minutes to pyridine (70 mL) at 0° C. To the CrO₃ mixture, a solution of kitasamycin (20 g, 26 mmol) in pyridine (30 mL) was added and stirred for 2.5 hours at room temperature. The mixture was neutralized with saturated aqueous NaHCO3 and extracted with ethyl acetate. The organic solution was dried over anhydrous Na₂SO4 and concentrated under vacuum. The residue was purified on a silica gel column (eluting with ethyl acetate: hexane/20:80 and increasing to 60:40) to give the title compound (4.3 g, 23%) as a light yellow solid.

[0239] MS (ESI) m/z 700 (M+H)⁺.

[0240]¹³C-NMR (100 MHz, CDCl₃): δ202.7, 202.6, 173.7, 173.6, 143.4, 141.4, 131.9, 122.5, 104.1, 97.2, 85.5, 79.3, 76.1, 73.2, 71.8, 69.5, 68.8, 67.8, 63.6, 62.1, 44.9, 42.0, 41.8, 38.1, 36.3, 32.1, 31.4, 31.1, 25.4, 20.4, 18.9, 18.7, 17.9, 17.6, 13.8.

[0241] Step 13b: Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3═H, R₄═OH and R^(p)=acetyl

[0242] A solution of the compound from step 13a (3.8 g, 4.9 mmol), Ac₂O (0.66 mL, 6.9 mmol), and triethyl amine (2.1 mL, 14.8 mmol) in dichloromethane (20 mL) was stirred for 16 hours at room temperature. The solvent was concentrated under vacuum. To the residue was added 0.3 N aqueous HCl (80 mL) and stirred for 16 hours. The reaction mixture was neutralized with NaHCO₃, extracted with dichloromethane, and dried over anhydrous Na₂SO₄. The solvent was evaporated under vacuum. Purification on silica gel column (eluting with dichloromethane: methanol: 28% aqueous NH₃/95:5:0.5) gave the title compound (800 mg, 27%) as a white solid.

[0243] MS (ESI) m/z 598 (M+H)⁺.

[0244]¹³C-NMR (100 MHz, CDCl₃): δ202.9, 202.7, 173.6, 169.1, 143.1, 141.1, 131.9, 122.7, 100.9, 85.8, 76.6, 72.9, 70.9, 70.5, 69.2, 68.9, 67.8, 61.8, 44.9, 41.6, 41.4, 31.8, 31.7, 31.0, 22.7, 21.8, 20.4, 17.9, 17.5.

[0245] Step 13c. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3═H, R4═OH and R^(p)═H

[0246] A solution of the compound from step 13b (100 mg, 0.17 mmol) in methanol (6 mL) was stirred for 16 hours at room temperature. The solvent was evaporated under vacuum to give the title compound (92 mg, 100%) as a white solid.

[0247] MS (ESI) m/z 556 (M+H)⁺.

[0248]¹³C-NMR (100 MHz, CDCl₃): δ202.8, 202.7, 173.7, 143.5, 141.2, 131.9, 122.5, 104.6, 85.5, 79.5, 73.5, 71.1 70.8, 70.2, 69.2, 68.8, 67.8, 62.1, 44.9, 43.6, 41.8, 38.3, 32.1, 20.4, 18.6, 17.9, 17.6.

Example 14

[0249] Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3═H, R₄═OH, and R^(p)═H

[0250] Step 14a. Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3═H, R4═OH and R^(p)=acetyl

[0251] To a solution of the compound from step 13b (0.8 mg, 1.34 mmol) in methanol (10 mL) was added acetyl chloride at 0° C. The pH of the solution was adjusted to pH<3. The mixture was stirred for 16 hours, neutralized with sodium bicarbonate, and concentrated. The residue was dissolved in dichloromethane, washed with saturated aqueous NaHCO₃ and water. The organic solution was dried over anhydrous Na₂SO₄ and concentrated under vacuum to provide the title compound (0.8 g, 93%).

[0252] MS (ESI) m/z 644 (M+H)⁺.

[0253]¹³C-NMR (100 MHz, CDCl₃): Δ203.2, 173.7, 169.1, 142.6, 140.7, 132.0, 123.1, 102.3, 100.9, 86.5, 76.8, 72.9, 70.8, 69.4, 68.9, 67.9, 61.7, 53.5, 50.8, 46.1, 44.9, 41.5, 32.9, 21.8, 20.5, 18.0.

[0254] Step 14b. Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3═H, R4═OH and R^(p)═H

[0255] A solution of the compound from step 14a in methanol is stirred for 16 hours at room temperature. The solvent is evaporated to give the title compound.

Example 15

[0256] Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3═H, R₄═OCH₂CHCH₂ and R^(p)=H

[0257] Step 15a. Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3═H, R4═OCH₂CHCH₂ and R^(p)=acetyl

[0258] A solution of the compound from step 13b (0.328 g, 0.5 mmol), t-butyl allylcarbonate (0.237 g, 1.5 mmol), 1,4-bis(diphenylphosphino)butane (42.6 mg, 0.1 mmol), tris(dibenzylideneacetone)dipalladium (45.8 mg, 0.05 mmol) in degassed tetrahydrofuran (5 mL) was heated at 68° C. for 2 hours and concentrated. Purification on silica gel column (eluting with ethyl acetate:hexane/20:80 and increased to 50:50) gave the title compound (60 mg, 18%) as a white solid.

[0259] MS (ESI) m/z 684 (M+H)⁺.

[0260]¹³C-NMR (100 MHz, CDCl₃): δ203.2, 173.7, 169.3, 142.5, 140.5, 135.2, 132.1, 123.2, 117.0, 102.4, 100.6, 86.4, 79.8, 76.2, 73.2, 72.4, 71.2, 69.0, 68.9, 67.9, 61.8, 53.4, 50.9, 44.9, 41.6, 41.5, 38.5, 33.0, 30.9, 21.7, 20.4, 18.2, 17.9.

[0261] Step 15b. Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3═H, R4═OCH₂CHCH₂ and R^(p)═H

[0262] A solution of the compound from step 15a in methanol is stirred for 16 hours at room temperature. The solvent is evaporated under vacuum to give the title compound.

Example 16

[0263] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3═H, R4═OCH₂CHCH₂ and R^(p)═H

[0264] Step 16a. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3═H, R4═OCH₂CHCH₂ and R^(p)═H

[0265] To a solution of the compound from step 15a (60 mg, 0.088 mmol) in acetonitrile (2 mL) was added water (10 mL) and TFA (0.04 mL, 0.52 mmol). The mixture was stirred for 16 hours at room temperature, diluted with saturated aqueous NaHCO₃ and extracted with dichloromethane. The solvent was evaporated under vacuum. Purification on silica gel column (eluting with ethyl acetate:hexane/50:50) gave the desire product (40.6 mg, 71%) as a white solid.

[0266] MS (ESI) m/z 638 (M+H)⁺.

[0267] Step 16b. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3═H, R4═OCH₂CHCH₂ and R^(p)═H

[0268] A solution of the compound from step 16a (40.6 mg, 0.063 mmol) in methanol (2 mL) was stirred overnight at room temperature. The solvent was evaporated under vacuum to give the title compound (35 mg, 93%) as white solid.

[0269] MS (ESI) m/z 596 (M+H)⁺.

[0270]¹³C-NMR (100 MHz, CDCl₃): δ203.2, 202.8, 173.9, 143.3, 141.1, 134.6, 132.0, 122.7, 117.3, 103.2, 85.6, 79.9, 73.2, 72.6, 70.2, 69.7, 68.9, 68.8, 67.9, 62.3, 62.2, 45.1, 43.2, 41.8, 38.1, 32.6, 32.0, 20.5, 18.2, 17.7.

Example 17

[0271] Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═OCHCHCH₂-(3-quinolyl) and R^(p)═H.

[0272] Step 17a. Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4=OCHCHCH₂-(3-quinolyl) and R^(p)=acetyl

[0273] A solution of the compound from step 10a (100 mg, 0.138 mmol), 3-bromoquinoline (57.4 mg, 0.276 mmol), tri-o-tolylphosphine (17 mg, 0.055 mmol), triethyl amine (0.038 ml, 0.276 mmol), and palladium (II) acetate (6.2 mg, 0.027 mmol) in degassed acetonitrile (3 mL) was heated at 80° C. for 16 hours and concentrated. Purification on a silica gel column (eluting with ethyl acetate:hexane:triethyl amine/70:30:1) gave the title compound (51 mg, 43%).

[0274] MS (ESI) m/z 853 (M+H)⁺.

[0275] Step 17b. Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═OCHCHCH₂-(3-quinolyl) and R^(p)═H

[0276] A solution of the compound from step 17a in methanol is stirred for 16 hours at room temperature to give the title compound.

Example 18

[0277] Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OCHCHCH₂-(3-quinolyl) and R^(p)═H

[0278] Step 18a. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OCHCHCH₂-(3-quinolyl) and R^(p)=acetyl

[0279] To a solution of the compound from step 17a (51 mg, 0.06 mmol) in acetonitrile (2 mL) was added water (10 mL) and TFA (0.04 mL, 0.52 mmol). The mixture was stirred for 16 hours at room temperature, diluted with saturated aqueous NaHCO₃ and extracted with dichloromethane. The solvent was evaporated under vacuum to give the crude title compound (50 mg).

[0280] MS (ESI) m/z 807 (M+H)⁺.

[0281] Step 18b. Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OCHCHCH2-3-quinolyl) and R^(p)═H

[0282] A solution of the compound from step 18a (50 mg) in methanol (2 mL) was stirred overnight at room temperature. The solvent was evaporated under vacuum. Purification on a silica gel column (eluting with acetone: hexane/1:6 and increasing to 4:6) gave the desired product (34 mg, 74%).

[0283] MS (ESI) m/z 765 (M+H)⁺.

[0284]¹³C-NMR (100 MHz, CDCl₃): δ203.2, 200.9, 170.8, 170.1, 152.1, 146.9, 146.5, 144.3, 140.3, 134.1, 132.8, 131.1, 129.3, 128.8, 128.3, 127.4, 126.8, 122.4, 103.8, 103.1, 85.0, 82.5, 72.3, 69.6, 69.5, 69.2, 68.7, 62.8, 44.5, 43.0, 41.6, 40.9, 36.9, 32.3, 30.8, 29.9, 27.9, 21.4, 20.7, 17.6, 14.1.

[0285] Although the invention has been described with respect to various preferred embodiments, it is not intended to be limited thereto, but rather those skilled in the art will recognize that variations and modifications may be made therein which are within the spirit of the invention and the scope of the appended claims. 

What is claimed is:
 1. A compound represented by the Formula:

wherein A is selected from the group consisting of; (1) CHO or a protected aldehyde, (2) CH₂X, wherein X is selected from the group consisting of; a. hydroxy or protected hydroxy, b. halogen, c. NR7R8, wherein R7 and R8 are each independently selected from hydrogen, C1-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic or R7R8 taken with the nitrogen atom to which they are connected form a 3- to 7-membered ring which may optionally contain a hetero function selected from the group consisting of —O—, —NH—, —N(C1-C6-alkyl)-, —N(aryl)-, —N(heteroaryl)- , —S—, —S(O)— and —S(O)₂—, d. NR7C(O)—R9, where R7 is as previously defined and R9 is selected from the group consisting of; i. C1-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, ii. C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, iii. C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, iv. aryl, v. substituted aryl, vi. heterocyclic, and vii. substituted heterocyclic e. NR7C(O)—NR8R9, where R7, R8, and R9 are as previously defined, f. S(O)_(n)-R10, where R10 is selected from the group consisting of aryl, substituted aryl, heterocyclic and substituted heterocyclic and where n=0, 1 or 2, g. S(O)_(n)-(C₁-C6-alkyl), optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, where n is as previously defined, h. S(O)_(n)-(C2-C6-alkenyl), optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, where n is as previously defined i. S(O)_(n)-(C2-C6-alkynyl), optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, where n is as previously defined, and j. O-M-Y, where M is (i) absent, (ii) —C(O)— (iii) —C(O)N(R7)—, where R7 is as previously defined, (iv) C1-C6-alkyl-N(R7)—, where R7 is as previously defined, (v) C2-C6-alkenyl-N(R7)—, where R7 is as previously defined, and (vi) C2-C6-alkynyl-N(R7)—, where R7 is as previously defined and where Y is (i) hydrogen (ii) C1-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, (iii) C2-C6-alkenyl, optionally substituted with one or more substituents selected from the grop consisting of halogen, aryl, substituted aryl, heterocyclic and substituted hetreocyclic, (iv) C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, (v) aryl, (vi) substituted aryl, (vii) heterocyclic, or (viii) substituted heterocyclic, (3) substituted or unsubstituted imidazole, arylimidazole or heteroarylimidazole, (4) substituted or unsubstituted oxazole, aryloxazole or heteroaryloxazole, (5) substituted or unsubstituted thioxazole, arylthioxazole or heteroarylthioxazole, (6) substituted or unsubstituted imidazoline, arylimidazoline or heteroarylimidazoline, (7) substituted or unsubstituted oxazoline, aryloxazoline or heteroaryloxazoline, and (8) substituted or unsubstituted thioxazoline, arylthioxazoline and (9) heteroarylthioxazoline, R1 and R2 are each independently selected from the group consisting of; (1) hydrogen, (2) hydroxy, (3) protected hydroxy, (4) OC(O)—C1-C12-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic, substituted heterocyclic, O—R7 and NR7R8 where R7 and R8 are as previously defined, (5) O—R7, where R7 is as previously defined, (6)halogen, (7) R1 and R2 taken together are oxo, and (8) NR7R8, where R7 and R8 are as previously defined; R3 is selected from the group consisting of; (1) hydrogen, (2) a hydroxy protecting group, and (3) C(O)—C1-C12 alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic, substituted heterocyclic, O—R7and NR7R8 where R7 and R8 are as previously defined; R4 is selected from the group consisting of; (1) hydrogen, (2) hydroxy, and (3) O-M-Y, where M and Y are as previously defined, and R^(p) is hydrogen or a hydroxy protecting group.
 2. A compound according to claim 1 wherein A=CHO, R1 and R2 taken together are O, R3 is acetyl, R4 is as defined in claim 1 and R^(p) is H.
 3. A compound according to claim 1 wherein A=CHO, R1 and R2 taken together are O, R3 is H, R4 is as defined in claim 1 and R^(p) is H.
 4. A compound according to claim 1 which is selected from the group consisting of: Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═H and R^(p)═H Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH-phenyl and R^(p)═H Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH(CH₂)₂-phenyl and R^(p)═H Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NHCH₂CHCH₂, and R^(p)═H Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NHCH₂-phenyl and R^(p)═H Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH-[4-NO₂-phenyl] and R^(p)═H Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NHCH₂-[4-OCH₃-phenyl] and R^(p)═H Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OC(O)NH₂ and R^(p)═H Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═OH, and R^(p)═H Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OCH₂CHCH₂ and R^(p)═H Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═H and R^(p)═H Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═H and R^(p)═H Compound of Formula I A=CHO, R1 and R2 taken together=O, R3═H, R4═OH and R^(p)═H Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3═H, R4═OH, and R^(p)═H Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3═H, R4═OCH₂CHCH₂ and R^(p)═H Compound of Formula I: A=CHO, R1 and R2 taken together=O, R3═H, R4═OCH₂CHCH₂, and R^(p)═H Compound of Formula I: A=CH(OCH₃)₂, R1 and R2 taken together=O, R3=acetyl, R4═OCHCHCH₂-(3-quinolyl) and R^(p)═H Compound of Formula I; A=CHO, R1 and R2 taken together=O, R3=acetyl, R4═OCHCHCH₂-(3-quinolyl) and R^(p)═H
 5. A pharmaceutical composition for treating bacterial infections comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, ester or prodrug thereof in combination with a pharmaceutically acceptable carrier.
 6. A method for treating bacterial infections comprising administering to a mammal in need of such treatment a pharmaceutical composition containing a therapeutically-effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, ester or prodrug thereof.
 7. A process for the preparation of a compound represented by Formula I, as defined in claim 1 comprising (a) reacting a compound represented by the formula

wherein A, R1, R2, and R3, are as defined in claim 1, R5 is —CH₂CH(CH₃)₂ or —CH₂CH₂CH₂ and R^(p) is a hydroxy protecting group with a dilute aqueous acid in an organic solvent at from about 0° C. to about 50° C. to provide a compound represented by Formula I wherein A, R1, R2, R3 and R^(p) are as defined in claim 1 and R4 is hydroxy, and (b) reacting a compound from step (a) represented by Formula I wherein A, R1, R2, and R3 are as defined in claim 1, R4 is hydroxy and R^(p) is a hydroxy protecting group with an isocyanate reagent in an aprotic solvent at from about 0° C. to about 50° C. to provide a compound represented by Formula I wherein A, R1, R2, R3 and R^(p) are as defined in claim 1 and R4 is —OC(O)NH-M-Y, wherein M and Y are as defined in claim 1..
 8. A process for the preparation of a compound represented by Formula I as defined in claim 1 comprising (a) reacting a compound represented by the formula

wherein A, R1, R2, and R3 are as defined in claim 1, R5 is CH₂CH(CH₃) and R^(p) is a hydroxy protecting group with an acid to provide a pH of from about 1 to about 4 in an alcoholic solvent to provide a compound represented by Formula I as defined in claim 1 wherein A, R1, R2, R3 and R^(p) are as defined in claim 1 and R4 is hydroxy, (b) reacting a compound of step (a) represented by Formula I as defined in claim 1 wherein A, R1, R2, R3 and R^(p) are as defined in claim 1 and R4 is hydroxy with an alkylating agent in the presence of a base in an aprotic solvent at from about −20° C. to about 60° C. to provide a compound represented by Formula I wherein A, R1, R2, R3, R4 and R^(p) are as defined in claim
 1. 9. A process for the preparation of a compound represented by Formula I as defined in claim 1 comprising reacting a compound represented by Formula I as defined in claim 1 wherein A, R1, R2, R3 and R^(p) are as defined in claim 1 and R4 is hydroxy with allyl bromide or propargyl bromide in the presence of a base in an aprotic solvent at from about −20° C. to about 60° C. to provide a compound represented by Formula I wherein A, R1, R2, R3, and R^(p) are as defined in claim 1 and R4 is —OCH₂CHCH₂ or —OCH₂CCH.
 10. A process for the preparation of a compound represented by Formula I as defined in claim 1 comprising (a) reacting a compound represented by Formula I as defined in claim 1 wherein A, R1, R2, R3 and R^(p) are as defined in claim 1 and R4 is hydroxy with a sulphonyl halide in an aprotic solvent in the presence of a base at from about −78° C. to room temperature to provide an intermediate, (b) reacting said intermediate from step (a) with an iodide compound in an aprotic solvent at from room temperature to about 100° C. to provide a 4′ intermediate, and (c) removing the 4′ iodide functionality by reducing the intermediate from step (b) to provide a compound represented by Formula I as defined in claim
 1. 